1-10 of 10
A Stamatoullas
Close
Sort by
Journal Articles

Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.

Christian Rose, MD, Sabine Brechignac, MD, Dominique Vassilief, MD, Odile Beyne-Rauzy, MD, A. Stamatoullas, MD, Dalila Larbaa, MD, Agnes Guerci, MD, L. Roy, MD, Lydia Dumazert, MD, Beatrice Mahe, MD, S. Cheze, MD, Bruno Quesnel, MD PD, Dominique Bordessoule, MD PD, Francois Dreyfus, MD PD, Pierre Fenaux, MD PD
Journal: Blood
Blood (2007) 110 (11): 249.
https://doi.org/10.1182/blood.V110.11.249.249
Published: 2007
Journal Articles

MDS with Isolated Neutropenia or Thrombocytopenia. Incidence and Characteristics in the Groupe Francophone des Myélodysplasies (GFM) Registry.

Sophie Park, MD, V. Andrieu, R. Sapena, G. Leroux, A. Stamatoullas, M.P. Callat, O. Beyne-Rauzy, J. Mairesse, M.P. Chaury, Herve Dombret, V. Siguret, Norbert Vey, G. Lepeu, A. Guerci, S. Cheze, Pierre Fenaux, F. Dreyfus
Journal: Blood
Blood (2007) 110 (11): 2456.
https://doi.org/10.1182/blood.V110.11.2456.2456
Published: 2007
Journal Articles

Bortezomib + Low Dose Cytarabine in Int-2 and High Risk MDS. Interim Results of a Phase I/II Trial by the GFM.

Shanti Natarajan, Pierre Fenaux, Norbert Vey, A. Guerci, I. Coulibaly, A. Charbonnier, C. Ravoet, S. Courby, G. Etienne, M.P. Chaury, S. Cheze, A. Stamatoullas, L. Legros, E. Berger, A. Lescoute, S. Vaultier, F. Dreyfus
Journal: Blood
Blood (2007) 110 (11): 1453.
https://doi.org/10.1182/blood.V110.11.1453.1453
Published: 2007
Journal Articles

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

S. Burcheri, MD, T. Prebet, MD, O. Beyne-Rauzy, MD, R.M. Mbida, MD, N. Hoarau, MD, L. Legros, MD, C. Ravoet, MD, F. Dreyfus, MD, A. Stamatoullas, MD, M.P. Chaury, MD, J. Delaunay, MD, G. Laurent, MD, N. Vey, MD, L. Ades, MD, C. Gardin, MD, Pierre Fenaux, MD
Journal: Blood
Blood (2007) 110 (11): 820.
https://doi.org/10.1182/blood.V110.11.820.820
Published: 2007
Journal Articles

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

S. Park, C. Kelaidi, S. Grabar, O. Beyne-Rauzy, S. Cheze, V. Bardet, M. Escoffre-Barbe, C. Ravoet, A. Ferrant, N. Vey, H. Dombret, B. Mahe, L. Mannone, L. Legros, L. Aljassem, A. Stamatoullas, D. Vassilief, M.C. Quarre, L. Ades, V. Andrieux, S. Giraudier, S. de Botton, N. Casadevall, P. Fenaux, F. Dreyfus
Journal: Blood
Blood (2006) 108 (11): 522.
https://doi.org/10.1182/blood.V108.11.522.522
Published: 2006
Journal Articles

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

J. Tamburini, C. Elie, D. Vassilief, M.C. Quarre, O. Beyne-Rauzy, M. Gardembas, A. Aouba, C. Berthou, L. Sanhes, A. Guerci, A. Stamatoullas, F. Bauduer, J.J. Sotto, L. Legros, S. Vaultier, P. Fenaux, F. Dreyfus, D. Bouscary
Journal: Blood
Blood (2006) 108 (11): 2673.
https://doi.org/10.1182/blood.V108.11.2673.2673
Published: 2006
Journal Articles

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

L. Ades, H. Mohamed, D. Vassilief, E. Berger, B. Slama, N. Vey, R. Delarue, O. Beyne-Rauzy, A. Guerci, S. Cheze, X. Thomas, A. Stamatoullas, M. Gardembas, F. Bauduer, A. Kolb, M.C. Chaury, L. Legros, G. Damaj, F. Hamza, S. Vaultier, F. Dreyfus, P. Fenaux
Journal: Blood
Blood (2005) 106 (11): 2537.
https://doi.org/10.1182/blood.V106.11.2537.2537
Published: 2005
Journal Articles

Thalidomide for the Treatment of Low Risk Myelodysplasia.

D. Bouscary, MD-PhD, M. C. Quarre, MD, D. Vassilief, MD, O. Beyne Rouzy, MD, A. Aouba, MD, C. Berthou, MD, C. Gardembas, MD, L. Sanhes, MD, A. Guerci, MD, B. Mahe, MD, A. Stamatoullas, MD, F. Bauduer, MD, J. J. Sotto, MD, L. Legros, MD-PhD, S. Vaultier, ARC, P. Fenaux, MD-PhD, F. Dreyfus, MD
Journal: Blood
Blood (2004) 104 (11): 1438.
https://doi.org/10.1182/blood.V104.11.1438.1438
Published: 2004
Journal Articles

Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000).

L. Ades, E. Raffoux, S. Chevret, S. de Botton, A. Guerci, A. Pigneux, A.M. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, T. Pabst, S. Meyer-Monard, F. Maloisel, E. Deconinck, D. Caillot, N. Gratecos, J.J. Sotto, A. Ferrant, P. Turlure, X. Thomas, N. Fegueux, P. Brault, O. Reman, P. Chevallier, P. Travade, V. Leblond, G. Leverger, A. Stamatoullas, C. Pautas, B. Beve, C. Chomienne, H. Dombret, L. Degos, P. Fenaux
Journal: Blood
Blood (2004) 104 (11): 391.
https://doi.org/10.1182/blood.V104.11.391.391
Published: 2004
Journal Articles

Prognostic value of chromosomal abnormalities in follicular lymphoma

H Tilly, A Rossi, A Stamatoullas, B Lenormand, C Bigorgne, A Kunlin, M Monconduit, C Bastard
Journal: Blood
Blood (1994) 84 (4): 1043–1049.
https://doi.org/10.1182/blood.V84.4.1043.1043
Published: 1994